A new plain language summary of publication has been published in Future Microbiology called ‘A plain language summary of how lefamulin alone can be used to treat pneumonia caught outside of the hospital due to common bacterial causes, including drug-resistant bacteria’. The article summarises the results of two clinical studies that looked at how the new antibiotic lefamulin (brand name, Xenleta®) can be used to treat bacterial pneumonia caught outside a hospital (also called community-acquired bacterial pneumonia, or CABP).
Read the full article here.
Click here and here to read the two original articles on which this summary is based.